国家: 美国
语言: 英文
来源: NLM (National Library of Medicine)
MIGLUSTAT (UNII: ADN3S497AZ) (MIGLUSTAT - UNII:ADN3S497AZ)
Actelion Pharmaceuticals US, Inc.
miglustat
miglustat 100 mg
ORAL
PRESCRIPTION DRUG
ZAVESCA is indicated as monotherapy for the treatment of adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option (e.g. due to allergy, hypersensitivity, or poor venous access). None. Risk Summary Based on findings from animal reproduction studies, ZAVESCA may cause fetal harm when administered to a pregnant woman. Available data from postmarketing case reports with ZAVESCA use in pregnancy are insufficient to assess a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There are risks associated with symptomatic Type I Gaucher disease in pregnancy, including hepatosplenomegaly and thrombocytopenia (see Clinical Considerations). Advise pregnant women of the potential risks to the fetus. In animal reproduction studies, miglustat was maternally toxic in rabbits at exposures near the expected human therapeutic dose and caused embryo-fetal toxicitie
ZAVESCA is supplied in hard gelatin capsules containing 100 mg of miglustat. ZAVESCA ® 100 mg capsules are white opaque with "OGT 918" printed in black on the cap and "100" printed in black on the body. ZAVESCA ® 100 mg capsules are packed in blister cards. Six blister cards of 15 capsules are supplied in each carton. NDC 66215-201-90: carton containing 90 capsules NDC 66215-201-15: blister card containing 15 capsules Storage Store at 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C to 30°C (59°F to 86°F), [See USP Controlled Room Temperature]. Keep out of reach of children.
New Drug Application
ZAVESCA- MIGLUSTAT CAPSULE ACTELION PHARMACEUTICALS US, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ZAVESCA SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ZAVESCA. ZAVESCA (MIGLUSTAT) CAPSULES, FOR ORAL USE INITIAL U.S. APPROVAL: 2003 INDICATIONS AND USAGE ZAVESCA is a glucosylceramide synthase inhibitor indicated as monotherapy for treatment of adult patients with mild/moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option ( 1.1). DOSAGE AND ADMINISTRATION Recommended dosage is 100 mg administered orally three times a day at regular intervals ( 2.1). May reduce dosage to 100 mg once or twice a day in some patients due to tremor or diarrhea ( 2.1). Adjust in patients with renal impairment ( 2.2): RENAL IMPAIRMENT ADJUSTED CREATININE CLEARANCE (IN ML/MIN/1.73 M ) RECOMMENDATIONS Mild 50 – 70 Start dose at 100 mg twice a day Moderate 30 – 50 Start dose at 100 mg once a day Severe <30 Use is not recommended DOSAGE FORMS AND STRENGTHS Capsules: 100 mg ( 3) CONTRAINDICATIONS None ( 4). WARNINGS AND PRECAUTIONS Peripheral neuropathy: Perform baseline and follow-up neurological evaluations at 6-month intervals in all patients ( 5.1). Tremor: Reduce dose to ameliorate tremor or discontinue treatment if tremor does not resolve within days of dose reduction ( 5.2). Diarrhea and weight loss: Evaluate for underlying gastrointestinal disease in patients who do not respond to usual interventions (e.g. diet modification) ( 5.3). Reductions in Platelet Count: Mild reductions in platelet counts without association with bleeding were observed in some patients. Monitoring of platelet counts is recommended ( 5.4). ADVERSE REACTIONS The most common adverse reactions (incidence ≥5%) are: diarrhea, weight loss, stomach pain, gas, nausea and vomiting headache including migraine, tremor, leg cramps, dizziness, weakness, vision problems, thrombocytopenia, muscle cramps, back pain, constipation, dry mouth 阅读完整的文件